The focus of the Lewin group is to understand why HIV infection persists on antiretroviral therapy and to develop new strategies to eliminate latency. The lab also researches factors that drive liver disease in HIV-hepatitis B virus co-infection. The lab is also actively involved in COVID in relation to pathogenesis, the use of primary tissue models, and developing therapeutics using gene editing strategies.
